MedPath

Study to Determine the Optimal Starting Dose of FSH in a Low- Dose-Stepup Regime

Not Applicable
Conditions
WHO group II ovarian failure (first-grade amenorrhea, oligomenorrhea, or anovulatory cycle), luteal phase insufficiency, or unexplained infertility
Registration Number
JPRN-UMIN000015669
Lead Sponsor
Department of Obstetrics and Gynecology,Tokushima University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1)WHO group I ovarian failure (second-grade [central] amenorrhea) 2)WHO group III ovarian failure (ovarian amenorrhea) 3)Hyperprolactinemia

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of subjects whose dominant follicles grow to a mean diameter of 18 mm within 10 days after starting FSH administration and the cumulative FSH dose needed to reach this endpoint
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath